Cargando…
The ULK1/2 and AMPK Inhibitor SBI-0206965 Blocks AICAR and Insulin-Stimulated Glucose Transport
The small molecule kinase inhibitor SBI-0206965 was originally described as a specific inhibitor of ULK1/2. More recently, it was reported to effectively inhibit AMPK and several studies now report its use as an AMPK inhibitor. Currently, we investigated the specificity of SBI-0206965 in incubated m...
Autores principales: | Knudsen, Jonas R., Madsen, Agnete B., Persson, Kaspar W., Henríquez-Olguín, Carlos, Li, Zhencheng, Jensen, Thomas E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177789/ https://www.ncbi.nlm.nih.gov/pubmed/32231045 http://dx.doi.org/10.3390/ijms21072344 |
Ejemplares similares
-
Investigation of the specificity and mechanism of action of the ULK1/AMPK inhibitor SBI-0206965
por: Ahwazi, Danial, et al.
Publicado: (2021) -
Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell Renal Carcinoma and the Antitumor Effects of SBI-0206965
por: Lu, Jun, et al.
Publicado: (2018) -
The inhibitor of autophagy SBI-0206965 aggravates atherosclerosis through decreasing myeloid-derived suppressor cells
por: Wang, Bo, et al.
Publicado: (2020) -
Low‐ and high‐protein diets do not alter ex vivo insulin action in skeletal muscle
por: Li, Zhencheng, et al.
Publicado: (2018) -
Benzimidazole derivative small-molecule 991 enhances AMPK activity and glucose uptake induced by AICAR or contraction in skeletal muscle
por: Bultot, Laurent, et al.
Publicado: (2016)